PROTAC BRD9 Degrader-1 is primarily used in targeted protein degradation, a cutting-edge approach in drug discovery and therapeutic development. It is designed to selectively degrade the BRD9 protein, which is implicated in various diseases, including cancer. By leveraging the ubiquitin-proteasome system, this molecule effectively marks BRD9 for destruction, offering a novel way to study its biological functions and potential as a therapeutic target. Its application is particularly significant in research focused on understanding the role of BRD9 in chromatin remodeling and gene regulation, as well as in developing treatments for cancers where BRD9 plays a critical role. Additionally, it serves as a valuable tool in chemical biology for exploring protein degradation pathways and validating drug targets.